cbdMD Inc YCBD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
-
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
-
Oasis Launches Hemp-Derived Mixer
-
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
-
cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
-
cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.66–0.70
- 52-Week Range
- $0.47–2.56
- Bid/Ask
- $0.67 / $0.68
- Shares Outstanding
- 10.50M
- Market Cap
- $6.99M
- Volume/Avg
- 160,556 / 1M
Key Statistics
- Price/Earnings (Normalized)
- 3.87
- Price/Sales
- 0.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 42
- Website
- https://www.cbdmd.com
Valuation
|
Metric
|
YCBD
|
|---|---|
Price/Earnings (Normalized) | 3.87 |
Price/Book Value | 0.77 |
Price/Sales | 0.29 |
Price/Cash Flow | 46.53 |
Price/Earnings
YCBD
Financial Strength
|
Metric
|
YCBD
|
|---|---|
Quick Ratio | 1.42 |
Current Ratio | 2.82 |
Interest Coverage | — |
Quick Ratio
YCBD
Profitability
|
Metric
|
YCBD
|
|---|---|
Return on Assets (Normalized) | −21.22% |
Return on Equity (Normalized) | −36.33% |
Return on Invested Capital (Normalized) | −32.71% |
Return on Assets
YCBD
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|^VG?v&<C | LOCK|?PG# | $69B | |||
| Haleon PLC ADR
HLN
| LOCK|H<>F^n^ | LOCK|^p | $43B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|&>@F!^! | LOCK|$n<! | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|S!P&Y>z | LOCK|%% | $32B | |||
| Viatris Inc
VTRS
| LOCK|jX<<@J | LOCK|N$X | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|Hn | LOCK|@T? | $13B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|C#Z%>$> | LOCK|k$ | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|#hb@$> | LOCK|^! | $8B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|Z#kB## | LOCK|#<#c | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|B#S>^j | LOCK|&^ | $1B |
United States